XML 33 R16.htm IDEA: XBRL DOCUMENT
v3.25.0.1

Accrued Expenses and Other Liabilities | 12 Months Ended
--- | ---
Dec. 31, 2024
Accrued Expenses and Other Liabilities |
Accrued Expenses and Other Liabilities | Note 9 — Accrued Expenses and Other Liabilities ​ The components of accrued expenses and other current liabilities were as follows: ​
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | December 31, | ​ | December 31,
​ |  | 2024 |  | 2023
​ | ​ | (in thousands)
Payroll and related benefits | ​ | $ | 30,398 | ​ | $ | 28,321
Warranty | ​ | ​ | 9,740 | ​ | ​ | 8,864
Operating lease liabilities | ​ | ​ | 3,757 | ​ | ​ | 4,025
Interest | ​ | ​ | 1,198 | ​ | ​ | 1,149
Professional fees | ​ | ​ | 1,969 | ​ | ​ | 1,834
Sales, use, and other taxes | ​ |  | 1,539 | ​ |  | 1,825
Contingent consideration | ​ | ​ | 702 | ​ | ​ | 1,814
Other | ​ |  | 5,892 | ​ |  | 9,792
Total | ​ | $ | 55,195 | ​ | $ | 57,624
​ Contract Liabilities and Performance Obligations ​ Contract liabilities consist of unsatisfied performance obligations related to advanced payments received and billing in excess of revenue recognized. The contract liability balance as of December 31, 2023 was approximately $118.0 million, of which the Company recognized approximately $97.0 million into revenue during the year ended December 31, 2024. ​ This reduction in contract liabilities was offset by new billings for products and services which were unsatisfied performance obligations to customers and revenue had not yet been recognized as of December 31, 2024. ​ As of December 31, 2024, the Company has approximately $57.0 million of remaining performance obligations on contracts with an original estimated duration of one year or more, of which approximately 77% is expected to be recognized within one year, with the remaining amounts expected to be recognized between one to three years. The Company has elected to exclude disclosures regarding remaining performance obligations that have an original expected duration of one year or less. ​ Other liabilities ​ Other Liabilities at December 31, 2024 was approximately $3.8 million, which included medical and dental benefits for former executives, asset retirement obligations, contingent consideration, and tax liabilities.

X
- Definition The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 720 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_PayablesAndAccrualsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration